Treatment of Malignant Oral Tumors in Dogs

The aim of this study was to evaluate the efficacy of metronomic chemotherapy in the palliative treatment of various malignant oral tumors in dogs. Our focus was to determine the effect of treatment on local disease control and to assess the tolerability and safety of the treatment in dogs with various oral malignancies. Metronomic chemotherapy with cyclophosphamide was used to treat 12 dogs and was combined with non-steroidal anti-inflammatory drugs in 6/12 (50%) of dogs.

A clinical benefit was observed in 6/12 (50%) patients 1 month and in 4/12 (33%) 3 months after treatment initiation. The median survival time of the dogs was 155 days (range 21-529 days). At the end of the observation period, the disease had progressed in 10/12 (83.3%) of the patients. Sterile hemorrhagic cystitis was the most commonly reported side effect of treatment, occurring in 4/12 (33.3%) dogs. The results of our study suggest that metronomic chemotherapy with cyclophosphamide can be, in a subset of dogs, beneficial in the palliation of malignant oral tumors.

“Metronomic Chemotherapy for Palliative Treatment of Malignant Oral Tumors in Dogs”. Nina Milevoj, et al. Front Vet Sci. 2022 Mar 31;9:856399. doi: 10.3389/fvets.2022.856399.

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

Tag

Like0

Dislike0

EVENTS

Edrapublishing

About Us Authors Contact Us Legal Notes Privacy Search

Top

Treatment of Malignant Oral Tumors in Dogs

Comments

List

Add

Tag

More news

40 Under 40: Dr. Cassi Fleming

CORRECTING and REPLACING Petwealth Emerges from Stealth with $1.7 Million in Funding, Landmark Partnerships, and a Mission to Become the Functional Health Platform for Pets

Unlocking the potential of ICT innovation in veterinary healthcare: The pathway to improve practices and business model

Canine papillomavirus: status of diagnostic methods and vaccine innovations

Analysing innovations among cattle smallholders to evaluate the adequacy of breeding programs

Newsletter

News of interest

Veterinary Professions Advising Center: an innovative approach to preveterinary advising for Animal Science students

Notes from the Field: Strengthening vaccine confidence through science, policy, and public engagement

Landmark study finds striking parallels in feline, human cancers

Feline oral squamous cell carcinoma: recent advances and future perspectives

EVENTS